QQQ   296.51 (+1.08%)
AAPL   146.73 (+1.92%)
MSFT   248.70 (+0.28%)
META   152.12 (+3.27%)
GOOGL   99.64 (+2.17%)
AMZN   102.25 (+3.05%)
TSLA   178.41 (+11.32%)
NVDA   202.29 (+2.16%)
NIO   12.59 (+3.45%)
BABA   118.27 (-1.91%)
AMD   75.78 (+0.82%)
T   19.90 (-0.50%)
MU   63.28 (+0.76%)
F   13.21 (+2.24%)
CGC   2.90 (+5.07%)
GE   83.14 (+2.46%)
DIS   110.07 (+0.34%)
AMC   5.22 (-1.14%)
PFE   44.14 (-0.25%)
PYPL   82.38 (+1.94%)
NFLX   362.20 (-0.73%)
QQQ   296.51 (+1.08%)
AAPL   146.73 (+1.92%)
MSFT   248.70 (+0.28%)
META   152.12 (+3.27%)
GOOGL   99.64 (+2.17%)
AMZN   102.25 (+3.05%)
TSLA   178.41 (+11.32%)
NVDA   202.29 (+2.16%)
NIO   12.59 (+3.45%)
BABA   118.27 (-1.91%)
AMD   75.78 (+0.82%)
T   19.90 (-0.50%)
MU   63.28 (+0.76%)
F   13.21 (+2.24%)
CGC   2.90 (+5.07%)
GE   83.14 (+2.46%)
DIS   110.07 (+0.34%)
AMC   5.22 (-1.14%)
PFE   44.14 (-0.25%)
PYPL   82.38 (+1.94%)
NFLX   362.20 (-0.73%)
QQQ   296.51 (+1.08%)
AAPL   146.73 (+1.92%)
MSFT   248.70 (+0.28%)
META   152.12 (+3.27%)
GOOGL   99.64 (+2.17%)
AMZN   102.25 (+3.05%)
TSLA   178.41 (+11.32%)
NVDA   202.29 (+2.16%)
NIO   12.59 (+3.45%)
BABA   118.27 (-1.91%)
AMD   75.78 (+0.82%)
T   19.90 (-0.50%)
MU   63.28 (+0.76%)
F   13.21 (+2.24%)
CGC   2.90 (+5.07%)
GE   83.14 (+2.46%)
DIS   110.07 (+0.34%)
AMC   5.22 (-1.14%)
PFE   44.14 (-0.25%)
PYPL   82.38 (+1.94%)
NFLX   362.20 (-0.73%)
QQQ   296.51 (+1.08%)
AAPL   146.73 (+1.92%)
MSFT   248.70 (+0.28%)
META   152.12 (+3.27%)
GOOGL   99.64 (+2.17%)
AMZN   102.25 (+3.05%)
TSLA   178.41 (+11.32%)
NVDA   202.29 (+2.16%)
NIO   12.59 (+3.45%)
BABA   118.27 (-1.91%)
AMD   75.78 (+0.82%)
T   19.90 (-0.50%)
MU   63.28 (+0.76%)
F   13.21 (+2.24%)
CGC   2.90 (+5.07%)
GE   83.14 (+2.46%)
DIS   110.07 (+0.34%)
AMC   5.22 (-1.14%)
PFE   44.14 (-0.25%)
PYPL   82.38 (+1.94%)
NFLX   362.20 (-0.73%)
NASDAQ:RGNX

REGENXBIO - RGNX Stock Forecast, Price & News

$22.90
-0.10 (-0.43%)
(As of 01/27/2023 12:50 PM ET)
Add
Compare
Today's Range
$22.85
▼
$23.29
50-Day Range
$21.67
▼
$24.55
52-Week Range
$18.69
▼
$35.73
Volume
45,192 shs
Average Volume
292,550 shs
Market Capitalization
$991.43 million
P/E Ratio
14.77
Dividend Yield
N/A
Price Target
$41.43

REGENXBIO MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
80.4% Upside
$41.43 Price Target
Short Interest
Bearish
7.92% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.82
Upright™ Environmental Score
News Sentiment
0.32mentions of REGENXBIO in the last 14 days
Based on 16 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($6.32) to ($3.27) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.37 out of 5 stars

Medical Sector

258th out of 1,055 stocks

Biological Products, Except Diagnostic Industry

41st out of 170 stocks

See Top Rated MarketRank™ Stocks Here

RGNX stock logo

About REGENXBIO (NASDAQ:RGNX) Stock

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase III clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II;RGX-111, which is in Phase I/II clinical trial for treating mucopolysaccharidosis type I;RGX-181 which is in pre clinic stage for the treatment of late-infantile neuronal ceroid lipofuscinosis type II disease;RGX-202, to treat Duchenne muscular dystrophy which is in phase I/II clinical trial; and RGX-381, to treat the ocular manifestations of CLN2 disease which is in preclinical stage. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop novel gene therapies. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.

Receive RGNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for REGENXBIO and its competitors with MarketBeat's FREE daily newsletter.

RGNX Stock News Headlines

January 26, 2023 | americanbankingnews.com
SVB Leerink Cuts REGENXBIO (NASDAQ:RGNX) Price Target to $14.00
January 26, 2023 | americanbankingnews.com
REGENXBIO Inc. (NASDAQ:RGNX) to Post FY2024 Earnings of ($1.62) Per Share, SVB Leerink Forecasts
January 27, 2023 | Investing Trends (Ad)
"We need batteries. Literally everywhere."
Pretty much every technological megatrend today requires batteries. That includes EVs... 5G... AI... charging stations... and smart energy storage systems. Find out why the U.S. just added graphite to a list of super-critical minerals, calling it "essential for America's National Defense."
January 25, 2023 | americanbankingnews.com
FY2022 EPS Estimates for REGENXBIO Inc. (NASDAQ:RGNX) Lowered by SVB Leerink
January 25, 2023 | americanbankingnews.com
REGENXBIO (NASDAQ:RGNX) Shares Down 3.7% Following Analyst Downgrade
January 23, 2023 | finance.yahoo.com
REGENXBIO Announces Phase I/II Trial of RGX-202, a Novel Gene Therapy Candidate for Duchenne Muscular Dystrophy, is Active and Recruiting Patients
January 9, 2023 | finance.yahoo.com
REGENXBIO ANNOUNCES SENIOR LEADERSHIP PROMOTIONS
January 3, 2023 | finance.yahoo.com
REGENXBIO Announces Presentation at the 41st Annual J.P. Morgan Healthcare Conference
January 27, 2023 | PressReach (Ad)
Today's Featured Press Release
Small Pharma just reported clinical trial results.
December 21, 2022 | finance.yahoo.com
REGENXBIO Reports Update on Advancement of Programs for CLN2 Disease
December 8, 2022 | finance.yahoo.com
REGENXBIO Announces Completion of Dosing in the Phase I/II Trial of RGX-111 for the Treatment of Severe MPS I
December 3, 2022 | finance.yahoo.com
REGENXBIO (NASDAQ:RGNX) adds US$71m to market cap in the past 7 days, though investors from three years ago are still down 46%
November 3, 2022 | finance.yahoo.com
Regenxbio (RGNX) Reports Q3 Loss, Lags Revenue Estimates
November 3, 2022 | finance.yahoo.com
Regenxbio Says Diabetic Retinopathy Gene Therapy Shows Meaningful Improvements In Disease Severity
November 3, 2022 | finance.yahoo.com
REGENXBIO Presents Positive Interim Data from and the Expansion of Phase II ALTITUDE® Trial of RGX-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery
November 3, 2022 | finance.yahoo.com
REGENXBIO Reports Third Quarter 2022 Financial Results and Recent Operational Highlights
October 27, 2022 | finance.yahoo.com
REGENXBIO to Host Conference Call on November 3 to Discuss Third Quarter 2022 Financial Results, Recent Operational Highlights and Interim Data from Phase II ALTITUDE® Trial of RGX-314 for the Treatment of Diabetic Retinopathy
October 12, 2022 | finance.yahoo.com
Declining Stock and Decent Financials: Is The Market Wrong About REGENXBIO Inc. (NASDAQ:RGNX)?
October 7, 2022 | benzinga.com
Despite Solid Efficacy From Gene Therapy, This Analyst Cuts REGENXBIO's Price Target - Regenxbio (NASDAQ: - Benzinga
October 4, 2022 | finance.yahoo.com
Despite Solid Efficacy From Gene Therapy, This Analyst Cuts REGENXBIO's Price Target
October 4, 2022 | uk.investing.com
Alphabet To $114? Plus This Analyst Predicts $145 For Disney By Benzinga - Investing.com UK
October 4, 2022 | streetinsider.com
Regenxbio (RGNX) Reports Additional Positive Interim Data from Trials of RGX-314 - StreetInsider.com
October 3, 2022 | seekingalpha.com
REGENXBIO says additional phase 2 data bolsters RGX-314 for wet macular degeneration - Seeking Alpha
October 3, 2022 | benzinga.com
REGENXBIO Announces Additional Interim Data From Trials Of RGX-314 For The Treatment Of Wet AMD - Regenxb - Benzinga
September 27, 2022 | benzinga.com
REGENXBIO Announces Presentation at Chardan's 6th Annual Genetic Medicines Conference - Regenxbio (NASDAQ - Benzinga
September 27, 2022 | finance.yahoo.com
REGENXBIO Announces Presentation at Chardan's 6th Annual Genetic Medicines Conference
September 26, 2022 | streetinsider.com
REGENXBIO Announces Upcoming Presentations During the American Academy of Ophthalmology 2022 Annual Meeting - StreetInsider.com
See More Headlines
Receive RGNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for REGENXBIO and its competitors with MarketBeat's FREE daily newsletter.

RGNX Company Calendar

Last Earnings
11/03/2022
Today
1/27/2023
Next Earnings (Estimated)
3/07/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RGNX
CUSIP
N/A
CIK
1590877
Web
www.regenxbio.com
Phone
(240) 552-8181
Fax
N/A
Employees
372
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$41.43
High Stock Price Forecast
$61.00
Low Stock Price Forecast
$14.00
Forecasted Upside/Downside
+80.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
6 Analysts

Profitability

EPS (Most Recent Fiscal Year)
$1.55
Trailing P/E Ratio
14.77
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$127.84 million
Net Margins
15.34%
Pretax Margin
18.12%
Return on Equity
12.22%
Return on Assets
8.14%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.53
Quick Ratio
3.53

Sales & Book Value

Annual Sales
$470.35 million
Price / Sales
2.11
Cash Flow
$3.32 per share
Price / Cash Flow
6.89
Book Value
$17.87 per share
Price / Book
1.28

Miscellaneous

Outstanding Shares
43,294,000
Free Float
37,796,000
Market Cap
$991.43 million
Optionable
Optionable
Beta
0.99

Key Executives

  • Mr. Kenneth T. MillsMr. Kenneth T. Mills (Age 48)
    Pres, CEO & Director
    Comp: $1.72M
  • Mr. Vittal K. Vasista (Age 55)
    Exec. VP & Chief Financial Officer
    Comp: $1.25M
  • Mr. Curran M. Simpson M.S. (Age 61)
    Exec. VP and Chief Operations & Technology Officer
    Comp: $924.95k
  • Dr. Olivier Danos Ph.D. (Age 65)
    Exec. VP & Chief Scientific Officer
    Comp: $842.08k
  • Mr. Patrick J. Christmas II (Age 52)
    J.D., Exec. VP & Chief Legal Officer
    Comp: $1.11M
  • Ms. Tricia Truehart
    VP of Investor Relations & Corp. Communications
  • Mr. Andrew Yost
    VP of Corp. Devel.
  • Ms. Shiva G. Fritsch
    Chief People Officer
  • Dr. Laura A. Coruzzi J.D. (Age 70)
    Ph.D., Sr. VP of Intellectual Property
  • Dr. Ram Palanki Pharm.D.
    Sr. VP of Commercial Strategy & Operations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













RGNX Stock - Frequently Asked Questions

Should I buy or sell REGENXBIO stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for REGENXBIO in the last twelve months. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" RGNX shares.
View RGNX analyst ratings or view top-rated stocks.

What is REGENXBIO's stock price forecast for 2023?

6 brokers have issued 1 year price objectives for REGENXBIO's stock. Their RGNX share price forecasts range from $14.00 to $61.00. On average, they expect the company's share price to reach $41.43 in the next twelve months. This suggests a possible upside of 80.1% from the stock's current price.
View analysts price targets for RGNX or view top-rated stocks among Wall Street analysts.

How have RGNX shares performed in 2023?

REGENXBIO's stock was trading at $22.68 at the start of the year. Since then, RGNX stock has increased by 1.4% and is now trading at $23.00.
View the best growth stocks for 2023 here.

When is REGENXBIO's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023.
View our RGNX earnings forecast.

How were REGENXBIO's earnings last quarter?

REGENXBIO Inc. (NASDAQ:RGNX) posted its quarterly earnings results on Thursday, November, 3rd. The biotechnology company reported ($1.75) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.55) by $0.20. The biotechnology company earned $26.51 million during the quarter, compared to analysts' expectations of $29.77 million. REGENXBIO had a trailing twelve-month return on equity of 12.22% and a net margin of 15.34%.

What is Ken Mills' approval rating as REGENXBIO's CEO?

3 employees have rated REGENXBIO Chief Executive Officer Ken Mills on Glassdoor.com. Ken Mills has an approval rating of 68% among the company's employees.

What other stocks do shareholders of REGENXBIO own?

Based on aggregate information from My MarketBeat watchlists, some companies that other REGENXBIO investors own include AbbVie (ABBV), Micron Technology (MU), NVIDIA (NVDA), Voyager Therapeutics (VYGR), Amarin (AMRN), CRISPR Therapeutics (CRSP), Pfizer (PFE), QUALCOMM (QCOM), Gilead Sciences (GILD) and Block (SQ).

What is REGENXBIO's stock symbol?

REGENXBIO trades on the NASDAQ under the ticker symbol "RGNX."

Who are REGENXBIO's major shareholders?

REGENXBIO's stock is owned by a variety of retail and institutional investors. Top institutional investors include Hennion & Walsh Asset Management Inc. (0.24%), Harbor Capital Advisors Inc. (0.06%), SummerHaven Investment Management LLC (0.06%), Yousif Capital Management LLC (0.06%), Comerica Bank (0.05%) and Maryland State Retirement & Pension System (0.04%). Insiders that own company stock include Allan M Fox, Curran Simpson, Kenneth T Mills, Kenneth T Mills, Patrick J Christmas, Steve Pakola, Vittal Vasista and WR Stephens, Iii 2012 Trust.
View institutional ownership trends.

How do I buy shares of REGENXBIO?

Shares of RGNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is REGENXBIO's stock price today?

One share of RGNX stock can currently be purchased for approximately $23.00.

How much money does REGENXBIO make?

REGENXBIO (NASDAQ:RGNX) has a market capitalization of $995.67 million and generates $470.35 million in revenue each year. The biotechnology company earns $127.84 million in net income (profit) each year or $1.55 on an earnings per share basis.

How many employees does REGENXBIO have?

The company employs 372 workers across the globe.

How can I contact REGENXBIO?

REGENXBIO's mailing address is 9600 BLACKWELL ROAD SUITE 210, ROCKVILLE MD, 20850. The official website for the company is www.regenxbio.com. The biotechnology company can be reached via phone at (240) 552-8181 or via email at ir@regenxbio.com.

This page (NASDAQ:RGNX) was last updated on 1/27/2023 by MarketBeat.com Staff